Brief: Palisade Bio Inks Licensing Agreement With Giiant Pharma For Multiple Oral Drug Candidates For Inflammatory Bowel Disease

Palisade Bio

06/09/2023 16:13

Sept 6 (Reuters) - Palisade Bio Inc  PALI.O :
    * PALISADE BIO TRANSFORMS GI-FOCUSED PIPELINE THROUGH
EXCLUSIVE
WORLDWIDE LICENSING AGREEMENT WITH GIIANT PHARMA, INC. FOR
MULTIPLE ORAL DRUG CANDIDATES TARGETING INFLAMMATORY BOWEL
DISEASE
    * PALISADE BIO INC - UNDER TERMS OF LICENSE, OBTAINED RIGHTS
TO
DEVELOP, MANUFACTURE, AND COMMERCIALIZE ALL COMPOUNDS FROM
GIIANT
    * PALISADE BIO- LEAD PROGRAM, GT-2108 ADVANCING TOWARD
COMPLETION
OF IND-ENABLING STUDIES WITH IND FILING EXPECTED BY Q3 2024
    * PALISADE BIO: TO PAY PORTION OF DEVELOPMENT COSTS UNTIL
FIRST
APPROVAL OF IND/CTA & ASSUME DEVELOPMENT, MANUFACTURING,
COMMERCIALIZATION COSTS AFTER
    * PALISADE BIO INC - PER LICENSE, CO WILL PAY CERTAIN
MILESTONE
PAYMENTS (IN CASH OR STOCK AT PALISADE'S ELECTION) AND ROYALTY
PAYMENTS BASED ON SALES

Source text for Eikon:  ID:nGNX6Ytfqk 
Further company coverage:  PALI.O 

 ((Reuters.Briefs@thomsonreuters.com;))